Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 134

Sort by

Sort Order Select

Journal Articles

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 608.

https://doi.org/10.1182/blood-2024-207638

Published: 2024

Journal Articles

Belumosudil Is Efficacious for the Management of Heavily Pretreated and Prolonged Chronic Graft-Versus-Host Disease: A Retrospective Multi-Center Real-World Study By the Israel Association for Bone Marrow Transplantation and Cellular Therapy

Ben Varon, Ron Ram, Avichai Shimoni, Batia Avni, Sigal Grisariu, Vered Stavi, Yael Bar-On, Moshe Yeshurun, Ronit Elhasid, Aharon Gefen, Asaf Yanir, Odelia Amit, Dana Yehudai-Ofir, Israel Henig, Tsila Zuckerman

Blood (2024) 144 (Supplement 1): 7338.

https://doi.org/10.1182/blood-2024-206874

Published: 2024

Journal Articles

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4504.

https://doi.org/10.1182/blood-2024-200050

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

Blood (2024) 144 (Supplement 1): 912.

https://doi.org/10.1182/blood-2024-203520

Published: 2024

Journal Articles

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Blood (2024) 144 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2024-201029

Published: 2024

Journal Articles

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Blood (2024) 144 (Supplement 1): 1746.

https://doi.org/10.1182/blood-2024-203871

Published: 2024

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Ido Wolf, Odelia Amit, Ronit Yerushalmi, Yakir Moshe, Noga Shem-Tov, Gil Fridberg, Ivetta Danylesko, Irit Avivi Mazza, Avichai Shimoni

Blood (2023) 142 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2023-182826

Published: 2023

Journal Articles

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

Shalev Fried, Ivetta Danylesko, Ronit Marcus, Orit Itzhaki, Ronit Yerushalmi, Noga Shem-Tov, Inbal Sdayoor, Roni Shouval, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 6875.

https://doi.org/10.1182/blood-2023-178477

Published: 2023

Journal Articles

Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study

Ivetta Danylesko, Avichai Shimoni, Abraham Avigdor, Meirav Kedmi, Noga Shem-Tov, Ronit Yerushalmi, Maya Sasson, Dan Dominissini, Borje S. Andersson, Arnon Nagler

Blood (2023) 142 (Supplement 1): 4292.

https://doi.org/10.1182/blood-2023-178286

Published: 2023

Journal Articles

Prediction of Sinusoidal Obstructive Syndrome after Allogeneic Stem Cell Transplantation Using Liver Stiffness Measurement By Fibroscan

Ivetta Danylesko, Yana Davidov, Noga Shem-Tov, Ronit Yerushalmi, Ziv Ben-Ari, Arnon Nagler, Avichai Shimoni

Blood (2023) 142 (Supplement 1): 3542.

https://doi.org/10.1182/blood-2023-179990

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplantation with Myeloablative Compared with Reduced- Intensity Conditioning for AML and Mds; 20 Years Later

Avichai Shimoni, Ronit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Abraham Avigdor, Arnon Nagler

Blood (2023) 142 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2023-184520

Published: 2023

Journal Articles

Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy

Inbal Sdayoor, Roni Shouval, Shalev Fried, Ronit Marcus, Ivetta Danylesko, Ronit Yerushalmi, Noga Shem-Tov, Orit Itzhaki, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Michael J Segel, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2023-180115

Published: 2023

Journal Articles

Mitochondrial Fitness and Immune Function of Natural Killer Cells Are Impaired By the Multiple Myeloma (MM) Tumor Cells: The Role of MM Microenvironment Interactions

Katia Beider, Ilana Kalnitsky, Nira Varda-Bloom, Olga Ostrovsky, Avichai Shimoni, Hila Magen, Arnon Nagler

Blood (2023) 142 (Supplement 1): 875.

https://doi.org/10.1182/blood-2023-180516

Published: 2023

Journal Articles

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6908.

https://doi.org/10.1182/blood-2023-187338

Published: 2023

Journal Articles

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 648–650.

https://doi.org/10.1182/blood-2022-162286

Published: 2022

Journal Articles

CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma

Katia Beider, Noy Sharvit Boaron, Valeria Voevoda, Olga Ostrovsky, Ivetta Danylesko, Avichai Shimoni, Amnon Peled, Arnon Nagler

Blood (2022) 140 (Supplement 1): 5969–5970.

https://doi.org/10.1182/blood-2022-164646

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 2306–2307.

https://doi.org/10.1182/blood-2022-164637

Published: 2022

Journal Articles

Nivolumab Maintenance in First Complete Remission of Diffuse Large B-Cell Lymphoma

Meirav Kedmi, Elena Ribakovsky, Ohad Benjamini, Avichai Shimoni, Abraham Avigdor

Blood (2022) 140 (Supplement 1): 12071–12072.

https://doi.org/10.1182/blood-2022-158742

Published: 2022

Journal Articles

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

Liron Miller, Mor Freed-Freundlich, Tamer Hellou, Avichai Shimoni, Abraham Avigdor, Mudi Misgav, Jonathan Canaani

Blood (2022) 140 (Supplement 1): 5717–5718.

https://doi.org/10.1182/blood-2022-156096

Published: 2022

NARROW

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Belumosudil Is Efficacious for the Management of Heavily Pretreated and Prolonged Chronic Graft-Versus-Host Disease: A Retrospective Multi-Center Real-World Study By the Israel Association for Bone Marrow Transplantation and Cellular Therapy

CD19 CAR-T Cell Therapy Is Effective in Richter Transformation: A Multicenter Retrospective Analysis By the European Research Initiative on Chronic Lymphocytic Leukemia

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

CAR-Tography: Longitudinal Mapping of CAR-T Toxicities across B-Cell Malignancies Reveals Biologically Distinct and Prognostically Relevant Toxicity Phenotypes

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Impact of Broad-Spectrum Antibiotic Exposure on CAR-T Therapy Outcomes in B-Cell Lymphoma: A Multicenter International Study

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study

Prediction of Sinusoidal Obstructive Syndrome after Allogeneic Stem Cell Transplantation Using Liver Stiffness Measurement By Fibroscan

Allogeneic Stem Cell Transplantation with Myeloablative Compared with Reduced- Intensity Conditioning for AML and Mds; 20 Years Later

Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy

Mitochondrial Fitness and Immune Function of Natural Killer Cells Are Impaired By the Multiple Myeloma (MM) Tumor Cells: The Role of MM Microenvironment Interactions

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Nivolumab Maintenance in First Complete Remission of Diffuse Large B-Cell Lymphoma

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only